0 (0%)
Daily change

Thinking of trading PFIZER?

    1. Pfizer pharmaceutical pipeline is promising to say the least. Overall, Pfizer has up to 15 programs with blockbuster potential that could be approved by 2022. This pipeline has already delivered five regulatory approvals in just the first four months of 2019. 2. Pfizer bought back $8.9 billion worth of its shares in the first quarter. These buybacks reduce the number of outstanding shares and increase the value of the remaining ones. The company also invests in its dividend program, with the dividend currently yielding an attractive 3. 39%. Pfizer's continued focus on repurchasing its stock and paying solid dividends should help the company deliver nice long-term total returns.
Start Trading

Trading CFDs involves significant risk of loss

Get daily trading signals

  • Shares/Indices
  • Forex
  • Gold/Oil

Powered by

Trading CFDs involves significant risk of loss

How would you like to trade PFIZER?

Fondex cTrader features an impressive array of trading tools that can help you analyse the Forex market with efficiency and precision.
  • Tight spreads & reliable execution
  • 70+ pre-installed indicators
  • Custom indicators
  • 26 time frames
  • Live Sentiment data
  • Chart trading
  • Advanced Take Profit & Stop Loss
  • Depth of Market

Trading CFDs involves significant risk of loss

Fondex cTrader’s Copy functionality enables you to copy strategies from other traders or provide signals and charge a fee.
  • Vast selection of strategies to copy
  • Efficient risk management
  • Can start and stop copying at your will
  • Flexible allocation of funds
  • Detailed performance reports
  • Full transparency & access to historical data

Trading CFDs involves significant risk of loss

Use cBots to monitor and trade multiple Forex pairs at the same time. When you use cBots to trade, an algorithm opens and closes your positions without any decision-making on your part.

For beginners:

  • Great choice of available cBots for various trading strategies and risk tolerance levels
  • Simple Plug and Play functionality

For advanced traders:

  • Ability to create your own cBot or custom indicator

Trading CFDs involves significant risk of loss

This American multinational pharmaceutical corporation was founded 170 years ago in 1849 by German-American Charles Pfizer and his cousin Charles F. Erhart from Germany. It now trades with the ticker PFE in the NYSE and it is a component of the DJIA (since 2004), S&P 100 and S&P 500. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue, it is not difficult to imagine how they reached that level when by 1906, sales already totaled $3. 4 million.When it comes to the battle against makers of counterfeit prescription drugs, Pfizer has seen more success by pursuing civil lawsuits (trademark infringement) rather than criminal prosecution. A big move into the digital market that sped up the company's growth was May 2013, when Pfizer decided to start selling Viagra directly to patients via its website.In May 2019 the company announced it would acquire Therachon for $810 million, expanding its rare disease portfolio and in June Pfizer announced it would acquire Array Biopharma for $10.6 billion boosting its oncology pipeline. The company is also known for their efforts fighting greenhouse emissions, between 2002 and 2008, Pfizer reduced them by 20% and another 20% by 2012. Over the last five years Pfizer has delivered 67% price appreciation plus healthy dividends, compared with a 49% gain for the S&P 500 Index

1. Pfizer will soon lose patent exclusivity for its blockbuster drug Lyrica. This will weigh heavily on the company's growth throughout the rest of 2019 and into 2020. Lyrica was the source of $4.6 billion, or 8.6%, of the company's revenue last year. Pfizer expects $2. 6 billion of headwinds from LOE in 2019. 2. The market is obsessing over "Medicare for All" and other proposals being floated in advance of next year's election that could result in new pressures on drug prices. 3. Drug trials can fail and new competitors can arise.

Risk Disclaimer Fondex provides this content/feature as no more than information. In particular, no advice is intended to be provided or to be relied on as provided nor endorsed by Fondex, nor any solicitation or incentive provided to subscribe for or sell or purchase any financial instrument or to join and/or terminate any of the trading strategies. The Investor is solely responsible for the choice of the signal provider, choice of trading strategy, the choice whether to sell or purchase any financial instrument on his/her trading account and monitoring of the trading activities. All trading or investments you make must be pursuant to your own unprompted and informed self-directed position. Please keep in mind that past performance is no guarantee of future results.

For more information, please view the 'Risk Disclosure'